Shots:
Eurofarma gets exclusive rights to develop & commercialize cenobamate in Latin America. In exchange, SK will receive $15M up front & will be eligible to receive ~$47M milestones along with royalties
The agreement strengthens the dedication to developing therapies for CNS disorders & offers solutions for epilepsy sufferers globally. The agreement also broadens SK Biopharmaceutical’s footprint globally to provide cenobamate to the patient community
Enobamate has been approved in the US & EU for partial-onset seizures in adults & is also available under the brand name Xcopri. The four continents of North America, EU, Asia, and Latin America will now be served by SK
Ref: PRNewswire | Image: SK Biopharmaceuticals
